We run our own media, screen every claimant against your written criteria, and verify identity through LexisNexis before the lead reaches you. One lead, one firm — never resold, never recycled, not later as aged inventory. First leads land in your CRM in 7–10 days, and anything that misses your criteria is replaced free within 7 days.
We generate qualified claimants across the most active mass tort categories in the country. Select a tort type to learn more about our campaigns and lead quality.
GLP-1 receptor agonist claims for gastroparesis and severe GI injury, screened to the MDL 3094 diagnostic standard.
Contraceptive injection claims linked to meningioma brain tumors, with imaging confirmation captured at intake.
Occupational and secondary exposure claims with documented work history and a confirmed diagnosis.
Confirmed mesothelioma diagnosis with a traceable exposure source and an intact statute of limitations.
Chemical hair straightener claims linked to uterine cancer, ovarian cancer and endometriosis.
Ovarian cancer and mesothelioma claims tied to documented long-term talc use.
Minor exploitation and grooming claims. Phone-first intake — these cannot be qualified any other way.
Compulsive-design claims with documented behavioral, academic or clinical impact.
Adolescent mental health claims against platform design, with clinical documentation.
Running several torts at once? Most firms do. Mass tort volume follows litigation milestones, so it arrives in waves — firms often run more than one campaign at a time to keep intake staff productive between them. One account, one point of contact. If you are signing a tort that isn’t listed, ask: we monitor filings and FDA actions daily and regularly build campaigns before they get a page.
Get Pricing Across Torts
For over 15+ years, we have been delivering exceptional results for our clients nationwide, using our in-depth understanding of complex MDL litigation marketing and claimant acquisition experience.
Our mission is to be your trusted source and reliable partner in plaintiff acquisition services focused solely on mass torts.
Qualified leads are the middle of what we do, and the rest of this page covers them in detail. If you already know you want something further down the chain — claimants signed onto your paper, or your intake desk run for you — those are separate services, and you can skip straight to them.
Most companies selling mass tort leads are buying them from somebody else and marking them up. That is why the same claimant ends up at three firms, why nobody can produce a consent record when you ask, and why “exclusive” turns out to mean “not resold within thirty days.”
We buy the media ourselves — television, radio, connected TV, paid social, podcast inbounds and search — and we run the intake floor that screens what comes back. Nothing in the chain is subcontracted, which is the only reason we can tell you where a claimant came from, hand you the consent record, and stand behind the lead when your case manager reviews it.
That matters more than it used to. Under ABA Formal Opinion 501, a firm that hires a lead generator, sets no limits, and never asks how claimants were sourced is the party that violated the rules — not the vendor. You are supervising us under Model Rule 5.3 whether you asked to or not. We build the file so you can actually do that.
Our mass tort leads are exclusive in the literal sense: one lead, one firm, permanently. Not shared at delivery, not sold again later as aged inventory, not in any tort at any point.
Leads post to your CRM the moment they clear verification. Contact rates fall off a cliff within the first hour — we don’t let a verified claimant sit in a queue.
Wrong exposure window, prior representation, statute run out? Tell us and we replace it. No form, no restocking argument.
A spreadsheet of people who once clicked an ad is data, not leads. Every company selling mass tort legal leads works with the same three tiers whether they name them or not — and a price comparison across two different tiers tells you nothing at all.
Anyone who responded to an advertisement. No screening past a working phone number.
Cheap per unit, expensive in salaried intake hours. Most will not qualify, and you find out one call at a time.
Screened against your written criteria - injury or diagnosis confirmed, exposure window checked, statute intact, no prior representation.
Your team opens conversations with people who already fit the criteria you set at onboarding.
Retainer executed on your paper, QC-reviewed, delivered case-ready with the full file attached.
Highest price, lowest intake load. Detailed on our case acquisition page.
Qualified mass tort leads are what comes out of four screens, not what goes into them. Every inbound contact narrows through all four, and what reaches your CRM is what survived.
Your qualification rules become a signed document before a dollar of media runs. It is what the replacement guarantee is measured against.
Every inbound contact is risk-scored before a human picks up, then identity-matched through LexisNexis.
A trained agent asks the questions that decide whether the case is filable. Agents are paid on whether a claimant survives your review, never on volume.
The claimant posts to your CRM the moment they clear, with the evidence trail attached and retrievable years later.
Most campaigns that fail don’t fail at media. They fail at layers two and three, and the buying firm pays for it in intake hours rather than in a visible line on an invoice.
Cost per qualified lead swings by multiples across a single litigation’s life. Nothing about the claimants changes. The competition does. We track JPML filings, FDA actions and bellwether outcomes monthly — and we will tell you when a tort has become too expensive for your economics, including when saying so costs us the sale.
Stage One
A fresh FDA action, a new docket, or claims still moving through state court before consolidation. Awareness is low, competition is light, and cost per qualified lead sits at its floor. The trade-off is that the litigation’s trajectory is not yet proven.
Stage Two
The MDL is consolidated and discovery is underway. Qualifying criteria are settled, creative is proven, and campaigns run efficiently against a known standard. The sweet spot for most firms building a docket.
Stage Three
Settlement talk is circulating and the claimant pool is shrinking while every firm in the country advertises against it. Still worth entering if your docket economics support the price — but only then.
Where Our Campaigns Sit Today
205,540 claims pending across 162 active federal MDLs
Source: JPML, Distribution of Pending MDL Dockets by Actions Pending
Report dated 3 August 2026 · updated monthly
Asbestos and mesothelioma sit outside this table on purpose. Those claims run overwhelmingly through state courts and bankruptcy trusts rather than the federal MDL system, so pending-action counts understate them badly. We price them off trust filing volume and diagnosis rates instead. Ask and we’ll walk you through the difference.
No long-term contract, no minimum buried in the fine print.
Step 01
Tell us the litigation, the diagnosis or exposure requirements, geography, and monthly volume. We write it down — that document becomes what your replacement guarantee is measured against.
Step 02
Price depends on the tort, how strict your criteria are, and whether you want qualified leads or signed retainers. You get a real number for your campaign, not a range that fits nobody.
Step 03
Verified claimants start posting to your CRM within 7–10 days of setup on an active tort. Two to three weeks if we’re building a campaign from scratch. Anything off-criteria is replaced free within 7 days.
Every vendor selling mass tort leads describes itself the same way. These are the three commitments we put in the campaign agreement instead — each one checkable, each one something you can hold us to.
Fifteen-plus years of campaign data across every major MDL of that period. That archive is the only reason we can price a brand-new tort with any confidence — we already know what the claimant population costs to reach, which channel answers the phone, and how fast the number moves once a docket consolidates. A vendor without that history is quoting you a guess.
One lead, one firm. Not shared at delivery, and not resold later as aged inventory once the campaign closes — which is the loophole most “exclusive” contracts leave open. Read the definition in any competing quote carefully: some vendors define exclusive as “not sold twice within thirty days.” Ours has no clock on it.
Wrong exposure window, prior representation, statute already run? Tell us and we replace it at no cost. Replacement is measured against the written criteria sheet we build with your case managers before any media runs — not against a conversation someone half-remembers. That is precisely why we insist on getting the criteria document painfully specific rather than agreeable.
Tell us the litigation and the criteria your case managers actually use. We’ll come back with real numbers, a delivery timeline, and an honest read on whether that tort’s economics justify the spend right now. If they don’t, we’ll say so.
Looking for mass tort claimants for your docket? Tell us what you’re signing and we’ll respond within 24 hours with next steps and pricing.
By submitting, you consent to be contacted by InjuryCaseClaims.com regarding your inquiry. This does not constitute a binding agreement. All information is handled securely and confidentially.
Straight answers to what firms want to know before buying mass tort leads or signed cases from us. Anything not covered here, call and ask.